ALBERT LABS INTL. CORP. Net Assets
ALBERT LABS INTL. CORP. net assets. Based on the latest financial reports, ALBERT LABS INTL. CORP. (VB50) has net assets worth €- EUR (≈ $- USD) as of . Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€- ≈ $- USD) and total liabilities (€- ≈ $- USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore VB50 net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Net Assets of ALBERT LABS INTL. CORP. (2021–2022)
Net assets of ALBERT LABS INTL. CORP. from 2021 to 2022. This chart illustrates how ALBERT LABS INTL. CORP.'s net assets have evolved over time, based on quarterly financial data. See VB50 equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for ALBERT LABS INTL. CORP. (2021–2022)
The table below shows the annual net assets of ALBERT LABS INTL. CORP. from 2021 to 2022. For live market cap and overall valuation, see ALBERT LABS INTL. CORP. market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | €-365.32K ≈ $-427.09K |
+27.30% |
| 2021-12-31 | €-502.53K ≈ $-587.51K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ALBERT LABS INTL. CORP.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 705881300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
ALBERT LABS INTL. CORP. Net Assets Breakdown (December 2022)
ALBERT LABS INTL. CORP. net assets breakdown by equity component as of December 2022.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €9.01 Million | % |
| Total Equity | €-365.32K | 100.00% |
ALBERT LABS INTL. CORP. Competitors by Market Cap
The table below lists competitors of ALBERT LABS INTL. CORP. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PROPHECY DEFI INC.
F:V8M
|
$374.62K |
|
GeoVax Labs Inc
NASDAQ:GOVX
|
$374.90K |
|
Shoe Zone PLC
LSE:SHOE
|
$377.69K |
|
Global Gas Corporation
NASDAQ:HGAS
|
$378.40K |
|
Medivie Therapeutic Ltd
TA:MDVI
|
$371.77K |
|
Profusa, Inc. Common Stock
NASDAQ:PFSA
|
$371.00K |
|
LIVE MOTION GAMES ZY -10
F:4YM
|
$370.80K |
|
Hemogenyx Pharmaceuticals PLC
LSE:HEMO
|
$369.21K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ALBERT LABS INTL. CORP.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -502,526 to -365,317, a change of 137,209.
- Net loss of 7,058,813 reduced equity.
- New share issuances of 1,511,408 increased equity.
- Other factors increased equity by 5,684,614.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-7.06 Million | -1932.24% |
| Share Issuances | €1.51 Million | +413.73% |
| Other Changes | €5.68 Million | +1556.08% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares ALBERT LABS INTL. CORP.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €-0.01 | €0.01 | x |
| 2022-12-31 | €-0.01 | €0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ALBERT LABS INTL. CORP. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | €-1.83 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | €-7.02 Million |
Industry Comparison
This section compares ALBERT LABS INTL. CORP.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $446,628,955
- Average return on equity (ROE) among peers: -65.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ALBERT LABS INTL. CORP. (VB50) | €- | 0.00% | N/A | $372.07K |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $113.23 Million | -53.64% | 0.85x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-223.84 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $201.16 Million | -11.05% | 0.06x | $144.67 Million |
| PreveCeutical Medical Inc (18H) | $-5.78 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $4.10 Billion | -7.20% | 0.11x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $218.97 Million | -16.25% | 0.03x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $39.63 Million | -145.12% | 5.94x | $696.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About ALBERT LABS INTL. CORP.
Albert Labs International Corp., a biopharmaceutical drug discovery company, researches and develops drugs for psychedelic-assisted therapy for patients with urgent and unmet needs in Canada and the United Kingdom. It develops KRN-101, is a solution for cancer-related anxiety. The company is based in Burnaby, Canada.